SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paradigm Genetics -- PDGM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (94)1/4/2006 12:11:32 PM
From: Mike McFarland  Read Replies (1) of 101
 
CLDA shares are up to $20 from around
$17.5 in the last several hours of trading,
including yesterday.

Clinical Data showed net assets
of only 14M, but they are very
marginally profitable, at least
before buying Icoria.

I'll put it on my watch list and try to
post any interesting headlines I see
here on the pdgm/icor thread. I see this
too, a very small deal:

acquired Electa Lab s.r.l. in a cash transaction valued at approximately $1.8 million. Electa Lab, headquartered in Forli, Italy, is a leading worldwide supplier of Erythrocyte Sedimentation Rate ("ESR") instrumentation and related consumables, with annual sales of more than $3 million. Electa Lab has also developed proprietary technology for the safe decapping of blood collection tubes and is developing instruments and assays for the immunochemistry and coagulation markets. The acquisition will be accounted for as a purchase and is expected to be immediately accretive to Clinical Data's earnings.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext